Technology
Health
Biotechnology

Zealand Pharma

$20.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.43 (-2.12%) Today
+$0.41 (2.07%) After Hours

Why Robinhood?

You can buy or sell Zealand Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Zealand Pharma A/S American Depositary Shares, also called Zealand Pharma, is a biotechnology company that engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. Read More The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Glostrup, Denmark.

Employees
149
Headquarters
Glostrup, Zealand
Founded
1998
Market Cap
609.84M
Price-Earnings Ratio
Dividend Yield
Average Volume
8.69K
High Today
$20.27
Low Today
$19.96
Open Price
$20.27
Volume
5.46K
52 Week High
$20.85
52 Week Low
$11.51

Collections

Technology
Health
Biotechnology
2017 IPO

News

Seeking AlphaMay 14

Zealand Pharma's dasiglucagon successful in late-stage study; shares up 4% premarket

Zealand Pharma (NASDAQ:ZEAL) is up 4% premarket on light volume in reaction to its announcement of positive results from a confirmatory Phase 3 clinical trial evaluating dasiglucagon for the treatment of severe hypoglycemia (low blood sugar) in diabetes.

81
NasdaqMay 7

Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

Press release - No. 10 / 2019 Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome The Phase 3 extension trial will evaluate long-term safety and efficacy of glepaglutide and enrolls short bowel syndrome (SBS) patients that have completed the pivotal Phase 3 trial. The pivotal Phase 3 registration trial with glepaglutide for the treatment of SBS remains on track with results expected in 2020. Glepaglutide is a long-acting GLP-2 an...

35

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available May 16
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.